Charting the Course: Use of Clinical Pathways to Improve Value in Cancer Care
Menées dans un contexte américain, ces différentes études abordent les aspects économiques et financiers liés au cancer et à ses traitements, qu'il s'agisse de l'impact de la maladie sur l'emploi des personnes atteintes, des stratégies pour réduire les coûts des médicaments, du coût des programmes de prévention ou de dépistage, des difficultés financières des patients ayant survécu à la maladie, etc.
The last 2 decades have produced unparalleled innovation in oncology, with approximately 143 new drugs or indications approved by the US Food and Drug Administration (FDA) from January 1, 2013, to July 31, 2018.1 However, the cost of these new therapies has outstripped the benefits, with the launch price of new therapies increasing 12% per year, controlling for improvements in clinical benefit.2 Cancer-directed therapeutics and supportive care drugs now make up 37% of the total cost of cancer care for commercially insured UnitedHealthcare members and is even greater for the Medicare and Medicaid population with cancer. Among individuals who receive a drug as part of the cancer treatment plan, cancer drug costs represent over two thirds of the cost of treating their cancer.
Journal of Clinical Oncology , résumé, 2018